Evidence map›Paper›PMID 40303162›Full record

ArticleTransboundary and emerging diseases2024

Development and Application of an RPA-Based Rapid Point-of-Care Testing (POCT) Method for the Detection of Feline Panleukopenia Virus.

Liang Hong, Qian Huang, Yuhang Zhou, Qi Zheng, Shipeng Wang, Fangfang Chen, Xinyue Chang, Guosheng Jiang, Lisha Zha

Abstract read
In one paragraph

Article in Transboundary and emerging diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Emerging point-of-care technologies for bacterial pathogen detection.Journal of Zhejiang University. Science. B · 2026
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Liang HongInternational Immunology Centre College of Animal Science and Technology Anhui Agricultural University, Hefei 230036, Anhui, China.ORCID https://orcid.org/0009-0006-4379-6821
Qian HuangInternational Immunology Centre College of Animal Science and Technology Anhui Agricultural University, Hefei 230036, Anhui, China.ORCID https://orcid.org/0009-0008-4034-9035
Yuhang ZhouInternational Immunology Centre College of Animal Science and Technology Anhui Agricultural University, Hefei 230036, Anhui, China.ORCID https://orcid.org/0000-0001-9117-3094
Qi ZhengInternational Immunology Centre College of Animal Science and Technology Anhui Agricultural University, Hefei 230036, Anhui, China.ORCID https://orcid.org/0000-0001-5682-1885
Shipeng WangInternational Immunology Centre College of Animal Science and Technology Anhui Agricultural University, Hefei 230036, Anhui, China.ORCID https://orcid.org/0009-0008-8208-8654
Fangfang ChenInternational Immunology Centre College of Animal Science and Technology Anhui Agricultural University, Hefei 230036, Anhui, China.ORCID https://orcid.org/0000-0001-6408-1215
Xinyue ChangInternational Immunology Centre College of Animal Science and Technology Anhui Agricultural University, Hefei 230036, Anhui, China.ORCID https://orcid.org/0000-0001-7027-3889
Guosheng JiangInstitute of Basic Medicine Shandong Academy of Medical Sciences, Jinan 250062, Shandong, China.ORCID https://orcid.org/0000-0003-4394-6018
Lisha ZhaInternational Immunology Centre College of Animal Science and Technology Anhui Agricultural University, Hefei 230036, Anhui, China.ORCID https://orcid.org/0000-0002-5587-7104

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Feline panleukopenia (FP) is a highly prevalent and consequential disease that poses a substantial threat to both adult and juvenile cats across all geographical regions. The causative agent responsible for this disease is the feline panleukopenia virus (FPV). Therefore, it is imperative to develop a facile, efficient, and accurate detection method for FPV. Hence, a recombinase polymerase amplification-lateral flow dipstick assay (RPA-LFDA) method was specifically designed for the detection of FPV. The amplification process was optimized. This investigation focused on evaluating the expansion temperature detection system and revealed an optimal reaction temperature of 39°C. Then, primer combination screening involving nine groups identified F3R2 as the most effective primer set, while dilution ratio experiments determined that a 10-fold dilution yielded the best amplification products. Our findings demonstrated that the RPA-LFDA assay had an analytical sensitivity that was capable of detecting as low as 10 target copies per reaction. Furthermore, cross-reactivity tests demonstrated no interference between feline herpesvirus-1 (FHV-1) and feline calicivirus (FCV). To validate our newly developed method against existing techniques in clinical samples from three common sources on the market, we observed superior sensitivity and specificity compared to those of the colloidal gold method (CGM), with a higher positive detection rate using our nucleic acid detection system than CGM. Compared to qPCR as a reference standard, RPA-LFDA detected 39 out of 44 positive samples (including one false positive), whereas CGM detected 26 out of 44 positive samples. Based on the RPA-LFDA, the sensitivity was calculated to be 100%, the specificity was 83.33%, the mistake diagnostic rate was 16.67%, the omission diagnostic rate was 0%, and the overall accuracy reached 97.73%. Moreover, the positive coincidence rate was 97.44%, while the negative coincidence rate reached 100%. The agreement

Indexed as

Feline PanleukopeniaFeline Panleukopenia VirusNucleic Acid Amplification TechniquesPoint-of-Care TestingAnimalsCatsSensitivity and Specificity

Identifiers

PMID40303162
PMCPMC12016765

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.